Scholarlink

Background <p>Ocular myasthenia gravis (MG), while less severe than generalized MG, significantly impairs quality of life due to its impact on vision and daily activities. Immunotherapy is a key treatment, yet the optimal timing for initiation remains undefined.</p> Objective <p>To identify predictive factors for achieving minimal manifestations (MM) or better status in ocular MG patients receiving immunotherapy, with a focus on the role of early intervention.</p> Methods <p>We conducted a retrospective analysis of 48 ocular MG patients treated at our institution. Patients were categorized based on whether they achieved MM or better status. Clinical variables were analyzed using univariate, receiver-operating characteristic, and multivariate logistic regression analyses.</p> Results <p>MM or better status was achieved in 34/48 patients (median onset age: 55&#xa0;years). Time from symptom onset to immunotherapy initiation was significantly shorter in those who achieved MM or better status (median: 30&#xa0;days vs. 1095&#xa0;days; p &lt; 0.001). Receiver-operating characteristic analysis determined a 255-day cutoff for immunotherapy initiation, yielding sensitivity of 92.9% and specificity of 91.2% (AUC = 0.986, 95% CI: 0.962–1.000, p &lt; 0.001). Logistic regression confirmed early immunotherapy as an independent predictor.</p> Conclusions <p>Early initiation of immunotherapy (&lt; 255&#xa0;days from onset) significantly improves the likelihood of achieving MM or better status in ocular MG. These findings support the need for prompt diagnosis and treatment to optimize outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors of achieving minimal manifestations or better status in ocular myasthenia gravis with immunotherapy

  • 期刊论文

  • 发表日期：

    2025年3月4日

查看全文
  • Teppei Komatsu,
  • Haruhiko Motegi,
  • Masahiro Mimori,
  • Motohiro Okumura,
  • Marina Masui,
  • Hiroyuki Kida,
  • Masakazu Ozawa,
  • Hiromasa Matsuno,
  • Kenichi Sakuta,
  • Keiko Bono,
  • Kenichiro Sakai,
  • Hidetaka Mitsumura,
  • Yasuyuki Iguchi

摘要

Background

Ocular myasthenia gravis (MG), while less severe than generalized MG, significantly impairs quality of life due to its impact on vision and daily activities. Immunotherapy is a key treatment, yet the optimal timing for initiation remains undefined.

Objective

To identify predictive factors for achieving minimal manifestations (MM) or better status in ocular MG patients receiving immunotherapy, with a focus on the role of early intervention.

Methods

We conducted a retrospective analysis of 48 ocular MG patients treated at our institution. Patients were categorized based on whether they achieved MM or better status. Clinical variables were analyzed using univariate, receiver-operating characteristic, and multivariate logistic regression analyses.

Results

MM or better status was achieved in 34/48 patients (median onset age: 55 years). Time from symptom onset to immunotherapy initiation was significantly shorter in those who achieved MM or better status (median: 30 days vs. 1095 days; p < 0.001). Receiver-operating characteristic analysis determined a 255-day cutoff for immunotherapy initiation, yielding sensitivity of 92.9% and specificity of 91.2% (AUC = 0.986, 95% CI: 0.962–1.000, p < 0.001). Logistic regression confirmed early immunotherapy as an independent predictor.

Conclusions

Early initiation of immunotherapy (< 255 days from onset) significantly improves the likelihood of achieving MM or better status in ocular MG. These findings support the need for prompt diagnosis and treatment to optimize outcomes.